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Objectives: Survival in patients with chondrosarcomas has not improved over 40 years. Although 
emerging evidence has documented the efficacy of navigation-assisted surgery, the prognostic 
significance in chondrosarcomas remains unknown. We aimed to assess the clinical benefit of 
navigation-assisted surgery for pelvic chondrosarcomas involving the peri-acetabulum. 
Methods: We studied 50 patients who underwent limb-sparing surgery for periacetabular 
chondrosarcomas performed with navigation (n=13) without it (n=37) at a referral musculoskeletal 
oncology centre between 2000 and 2015. 
Results: The intralesional resection rates in the navigated n  non-navigated groups were 8% (n=1) 
and 19% (n=7), respectively; all bone resection margins were clear in the navigated group. The 
5-year cumulative risk of local recurrence was 23% and 56% in the navigated and non-navigated 
groups, respectively (p=0.037). There were no intra-operative complications related to use of 
navigation. There was a trend toward better functioal outcomes in the navigated group (mean 
MSTS score, 67%; range, 30 to 97%) than the non-navigated group (mean MSTS score, 60%; range, 
17 to 93%; p=0.412). At a mean follow-up of 63 months (range, 5 to 154 months), the 5-year 
disease-specific survival was 76% and 53% in the navigated and non-navigated group, respectively 
(p=0.085), whilst the 5-year progression-free survival w s 62% and 28% in the navigated and 
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non-navigated group, respectively (p=0.032). 
Conclusion: This study confirmed improved local control and progression-free survival with the use 
of computer navigation in patients with limb-salvage surgery for periacetabular chondrosarcomas, 





Chondrosarcomas are the second common primary malignant bone tumours, characterised by the 
production of the cartilaginous matrix [1]. Disappointingly, several studies have highlighted the lack 
of remarkable improvement in the survival of patients over the last 40 years [2, 3]. Previous 
investigations have determined that the poor prognostic factors for patients with chondrosarcoma are 
high-grade tumours and axial/pelvic tumour location [3-5]. In pelvic chondrosarcomas, 
intralesional/marginal margins, high-grade tumours, and larger tumours are negative prognostic 
factors for patient survival [6]. Intralesional/marginal margins and high-grade tumours are also 
associated with an increased risk of local failure [7, 8]. Of these, the only surgically modifiable 
factor for pelvic chondrosarcomas is the resection margin since chondrosarcomas are highly resistant 
to other treatment modalities, such as chemotherapy and radiotherapy [3, 5, 9-11]. However, 
achieving adequate resection margins in pelvic chondrosarcomas remains a major challenge for 
orthopaedic oncologists [6, 7, 12].  
Recent evidence has highlighted the advantages of computer navigation in orthopaedic 
oncology [13-19]. We have previously reported a reduced intralesional resection rate following 
navigated resection of pelvic and sacral tumours, in which clear bone resection margins were 
obtained in all cases [15]. In primary bone sarcomas of the posterior ilium and sacrum 
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navigated-assisted resection resulted in no intralesional resection margins and improved disease-free 
survival than the non-navigated resection group [19]. However, the efficacy of computer navigation, 
for peri-acetabular chondrosarcomas, with no adjuvant therapy, is limited to case reports and small 
series [13, 20, 21].  
The aim of this study was to evaluate the efficacy of the navigation-assisted surgery of 
chondrosarcomas involving the peri-acetabulum to address the following research questions: (1) 
Does the computer navigation improve local control? (2) Does the use of navigation affect the 
complication rate and functional outcome? (3) Does th  navigation-assisted surgery exert any effects 
on the survival of patients? 
 
Patients and Methods 
Eligibility 
We conducted a retrospective comparative study of patients who underwent limb-sparing surgery for 
chondrosarcomas involving the acetabulum at a single referral musculoskeletal oncology centre 
between November 2000 and August 2015. From a total of 98 patients eligible patients seen during 
the study period, patients who underwent excision for tumour localized to only ilium (PI, n = 20), 
pubis/ischium (PIII, n = 5), and sacrum (PIV, n= 4) were excluded. Patients who underwent curettage 
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as definitive treatment or those who required primay hindquarter amputation were also excluded 
from the analysis, because the navigation was not used for them (Supplementary Figure 1). A total 
of 50 patients matched after exclusion criteria. Tumo r resection was performed with navigation 
assistance in 13 patients, whose early results were, in part, reported in a previous study [15]. We 
compared this group of patients with a group of 37 patients who underwent tumour resection without 
the navigation assistance. 
The acetabular lesions were excised using a variety of resection types according to 
Enneking and Dunham’s classification system [22, 23]; iliac (PI), acetabular (PII), pubis or ischium 
(PIII), and sacral (PIV). Combinations of these resections were also performed, as follows: PI-II, 
resection of the iliac and acetabular regions; PII-III, resection of the acetabular and pubic/ischial 
regions; PI-II-III, resection of the iliac, acetabular, and pubic/ischial regions; PI-II-IV, resection f 
the iliac, acetabular, and sacral regions. After tumo r resection, the closest resection margin was 
evaluated by pathologists, who were highly experienced in bone and soft-tissue sarcomas, according 
to gross and microscopic examinations of the specimn. Regardless of whether navigation was used, 
the extent of margin width was evaluated at the bony a d soft-tissue resection margins. Bony 
margins were determined as the closest longitudinal istance between the tumour and the cut surface 
of the bone. Similarly, soft-tissue margins were determined as the closest distance between the 
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tumour that had extended to soft tissues and the cut surface of the soft-tissue. The resection margins 
were considered clear when no tumour cells were obsrved microscopically at the resection margins, 
while the margins were determined to be intralesional when tumour cells were observed at the 
resection margins. Clear margins were further classified as marginal margins (dissection through the 
pseudocapsule or reactive zone) or wide margins (dis ection entirely through the surrounding normal 
tissue) according to Enneking’s system [24]. Function was assessed using the Musculoskeletal 
Tumour Society (MSTS) system developed by Enneking et al. [25]. This system is based on the 
analysis of factors pertinent to the patient as a whole (pain, restriction in activities and/or occupation, 
and emotional acceptance) and factors specific to the affected limb (use of walking supports, walking 
ability, and gait) [25]. Each parameter is given a value, ranging from 0 to 5, according to specific 
criteria. The overall result is expressed as a total score of each parameter, which was then converted 
into a percentage of the maximum possible score. Following the institutional ethical approval, all 
patients provided appropriate consent, and all data were collected from the clinical records and 
imaging systems as part of the routine patient follow-up. 
 
Surgical Procedures 
Preoperatively, computed tomography (CT) and magnetic r sonance (MR) images, which were taken 
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as routine staging studies, were fused in the oncolgy-specific navigation system (Stryker Orthomap 
3D Navigation System II; Stryker, Kalamazoo, MI). The plane of the surgical resection margins was 
determined in the workstation before undertaking tumo r resection (Figure 1). Intraoperatively, a 
reference tracker was inserted into a stable portion of the pelvis, away from the tumour and the 
planned resection margin, regardless of tumour sizeand extraosseous growth into the intra- or 
extra-pelvic lesion. For tumours that required PII or PII+PIII (PI-uninvolved) resection, the tracker 
was placed onto the iliac crest, following surgical exposure of the iliac crest for its insertion. For 
tumours that required PI+II or PI+II+PIII (PI-involved) resection, the tracker was placed onto the 
iliac bone, at or close to the posterior superior il ac spine, following extensive exposure posteriorly 
using the extended ilioinguinal approach. Then, a paired-point and surface-point matching were 
performed. An overall registration error of < 1 mm was considered as acceptable, which was 
achieved for all patients. Next, the planned resection margins were marked on the bone under the 
navigation, and the osteotomy was performed with navigated surgical tools. Subsequently, the 
resected specimens were sent for histopathological analysis to confirm the diagnosis and evaluate the 
resection margins. 
 After tumour resection, patients underwent reconstruction with custom-made prostheses 
(Stanmore Implants, London, United Kingdom), ice-cram cone prostheses (Coned Hemi-Pelvis; 
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Stanmore Implants), irradiated autografts, or cemented total hip replacement (THR), which was 
selected according to the extent of the resection requi ed and the types of reconstruction available. In 
cases where reconstruction required a custom-made implant, the planned resection margins were 
determined according to the implant (Figure 1), which was discussed with engineers beforehand. In 
cases where an ice-cream cone prosthesis was used, the location and direction of the hole for a coned 
stem, depth of insertion, and abduction angle and anteversion of the acetabular component, were 
planned with navigation. In the non-navigated group, tumour resection and reconstruction was 
performed by measurements from pelvic landmarks according to pre-operative planning. Surgeries 
were performed by a single surgical team, consisting of the senior authors (LJ and RG). Surgical 
navigation was performed by the lead author (LJ) after appropriate training on the navigation 
equipment, and all surgeons’ skills were at a stable level. 
 
Statistical Analysis 
Analyses for local recurrence (LR) were completed with a competing risks framework. Analyses for 
local recurrence (LR) were completed with a competing risks framework. The LR at a given time 
was defined as the cumulative incidence of LR, with death regarded as the competing event, and the 
differences were calculated by Gray’s test. The progression-free survival (PFS) and disease-specific 
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survival (DSS) were calculated using the Kaplan-Meier analysis and a log-rank test. PFS was defined 
as the period from surgical resection to local recurence or distant metastasis and was censored at the
date of the latest follow-up or death due to other causes. DSS was defined as the period from the date 
of surgical resection to the last date when the patient was recorded to be alive or the date of 
tumour-related death. Univariate and multivariate analyses were performed using the and Cox 
regression model. Both the navigated and non-navigated groups were compared with regard to the 
presence of complication and functional outcome using Fisher’s exact test or Mann-Whitney U test. 
Differences were considered to be statistically significant at p<0.05. All statistical analyses were 
performed using the R 3.5.3 (R Foundation for Statistical Computing, Vienna, Austria) and the SPSS 




The study cohort comprised of 36 males and 14 femals, and the mean age at the time of resection 
was 53 years (range, 20 to 77 years). The mean tumour size was 10 cm (range, 5 to 20 cm) and the 
tumour grade based on the resected specimen was grade 1 in 7 (14%), grade 2 in 23 (46%), grade 3 
in 12 (24%), and dedifferentiated in 8 (16%). A discrepancy in 25 patients (50%) regarding the 
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diagnosis between biopsy and resected specimens was observed; these patients were all upgraded in 
the resected specimens compared with the biopsy specimens (grade 2 to 3 in 8; grade 1 to 2 in 8; 
grade 1 to 3 in 2; grade 1 to dedifferentiated in 3; benign to grade 1 in 2; and benign to grade 2 in ). 
The resected acetabular lesions according to the classification system of Enneking and Dunham [22, 
23] were type PII in 8 (16%), type PI–II resection in 14 patients (28%), type PII–III resection in 18 
(36%), and type PI–II–III in 8 (16%). Reconstructions after tumour resection were performed using 
custom-made prostheses in 23 patients (46%), ice-cream cone prostheses in 15 (30%), irradiated 
autografts in 7 (14%), and the other procedures in 5 (10%) (cemented THR and hip transposition, 
respectively). Three patients (6%) with dedifferentiated chondrosarcoma received adjuvant 
chemotherapy, and 2 patients (4%) received adjuvant r diotherapy. The mean follow-up was 63 
months (range, 5 to 154 months). The difference in the baseline characteristics between patients 
treated with and without navigation was not statistically significant in all variables (Table 1). 
 
Local control 
In the navigated group, a clear margin was obtained  12 patients (92%; wide, 61% and marginal, 
31%), and tumour contamination at the soft-tissue margins was observed in only a single patient 
(Table 1). No intralesional bony margins were observed in the navigated group. In the non-navigated 
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group, the margin was clear in 30 patients (81%; wide, 24% and marginal, 57%) and intralesional in 
7 (19%); tumour contamination was identified at thebone resection margin in 6 patients (superior 
pubic ramus in 4 patients and ilium in 2) and at the soft-tissue margin in 1 patient. In a comparison of 
the two groups, the rate of wide resection margins wa significantly higher in the navigated group 
than in the non-navigated group (62% versus 24%; p = 0.019). 
 Local recurrence (LR) occurred in 24 patients (48%); 7 LRs with intralesional margins, 13 
LRs with marginal margins and 4 LRs with wide margins were observed (p = 0.010; chi-square test). 
The competing risk analysis revealed that the 5-year cumulative incidence of LR was 45% in the 
entire cohort, whereas it was 88% in those with intralesional margins, 48% in those with marginal 
margins and 24% in those with wide margins (p = 0.007; Gray’s test; Figure 2A, Table 2). In a 
comparison according to the use of navigation, the 5-y ar cumulative LR incidence was 23% and 
56% in the navigated and non-navigated groups, respectively (p = 0.035; Gray’s test; Figure 2B, 
Table 2). The Cox regression hazard model revealed that the risk of local failure was significantly 
low in patients with wide margins (wide margins: HR, 0.184 [95% CI, 0.053–0.630] versus 
intralesional margins: HR, 1; p = 0.007) and in those in whom navigation was used (navigated: HR, 
0.269 [95% CI, 0.080–0.903] versus non-navigated; HR, 1; p = 0.034; Table 2). Among 22 patients 
with LR, 9 patients (41%) were determined to have a higher tumour grade than their primary tumour 
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was at diagnosis, as follows; grade 2 versus 3 in 4patients, grade 2 versus dedifferentiated in 3 
patients, grade 1 versus 2 in 1 patient and grade 1 versus dedifferentiated in 1 patient. 
 
Complication 
There was no intra-operative complication related to the navigation procedure. Complications related 
to surgery were seen in 34 patients (68%), with 9 (6 %) in the navigation-assisted group and 25 
(68%) in the non-navigation-assisted group (p = 0.600). These complications included dislocation in 
16 patients (32%), loosening in 4 (8%), implant/bone fracture in 4 (8%), deep/superficial infection in 
19 (38%), deep-vein thrombosis in 4 (8%), neurological complication in 4 (8%), wound necrosis in 2 
(4%), leg-length discrepancy in 2 (4%), pulmonary embolism in 2 (4%), lymphoedema in 2 (4%), 
visceral complication in 2 (4%) and heterotopic ossification in 1 (2%) (Table 3). The rate of major 
complications, which required at least one surgical intervention, was 31% and 46% in the navigated 
and non-navigated groups, respectively (p = 0.268). Except for tumour-related complications, we 
identified no statistical difference in the occurrenc  of surgical complications (Table 3). 
 
Functional outcome 
Among patients who were followed up for more than 12 months after surgery, the median MSTS 
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score in the navigated group was 66% (range, 30 to 97), whereas that of the non-navigated group was 
60% (range, 17 to 93; p = 0.412). The median MSTS score by custom-made prosthesis was 63% 
(range, 47 to 90) and 50% (range, 17 to 93) in the navigated and non-navigated groups, respectively 
(p = 0.285). Among patients who underwent reconstruction with ice-cream cone prostheses, the 
median MSTS scores were 74% (range, 50 to 97) and 70% (range, 40 to 90) in the navigated and 
non-navigated groups, respectively (p = 0.872). Overall, patients with a major complication or LR, 
which was a major cause of additional surgical interventions, had significantly poorer scores than 
those without a major complication or LR; the median score was 55% and 72% in patients with and 
without a major complication, respectively (p = 0.025), and 57% and 70% in patients with and 
without LR, respectively (p = 0.007). 
 
Survival outcome 
A total of 23 patients (46%) had distant metastasis w th a median period of 15 months 
postoperatively. Distant metastasis was observed in 4 patients (31%) in the navigated group and 19 
patients (51%) in the non-navigated group, but thisdifference was not statistically significant (p = 
0.170). The 5-year progression-free survival was 37% in the entire cohort; 62% and 28% in the 
navigated and non-navigated group, respectively (p = 0.032; Figure 3). The Cox regression hazard 
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model revealed that the histological grade, resection margin, and the use of navigation was 
significantly associated with progression-free survival (Table 4).  
The 5-year disease-specific survival was 57% in the entire cohort; 76% and 53% in the 
navigated and non-navigated group, respectively (p = 0.085; Figure 4). The Cox regression hazard 
model revealed that histological grade, tumour size, and LR were significantly associated with 
disease-specific survival (Table 4). When adjusted with these factors, histological grade and LR 
were independent prognostic predictors for disease-specific survival (Supplementary Table 1).  
 
Discussion 
Local control of pelvic chondrosarcomas involving the acetabulum is challenging. Puri et al. has 
reported that 18 of 21 LRs (85%) were chondrosarcomas among 91 patients with primary malignant 
bone tumours of the pelvis treated with limb-sparing resection [26]. Since surgical margin is a 
prognostic factor for LR, and LR has been proven to be a negative prognostic factor for survival, 
precise surgical management is crucial for improving outcomes. Since the surgical margin status is 
associated not only with LR [9, 27] but also survival [4] in the management of pelvic 
chondrosarcomas, precise surgical management is crucial to improve outcomes. Mavrogenis et al. 
stated that patients with any surgical margins other t an wide margins had a 1.75× higher risk of LR 
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(odds ratio, 1.754 [95% CI, 1.035–2.974]; p = 0.0378) compared with those with wide margins [28], 
while Bus et al. reported that patients with intralesional margins had a 2.36× higher risk of 
disease-specific death (hazard ratio, 3.56 [95% CI, 1.80–7.02]; p < 0.001) compared with those with 
wide margins [6]. We have introduced navigated resection for pelvic sarcomas since 2010, which 
significantly decreased the incidence rate of intralesional margin and contributed better outcome in 
local control [15]. In this study, we confirmed the significantly better outcome in local control and 
progression-free status by the navigation-assisted urgery. Overall, these findings validated the 
advantages of navigation in not only tumour resections but also reconstructions.  
 Although bony clear margin was achieved in all cases with navigated resection, the 
incidence of intralesional margin was observed in 1 patient in soft tissue despite the assistance of 
navigation. In this patient, the original tumour showed substantial involvement to soft tissue inward 
to the abdominal cavity, where the tumour contaminatio  was observed. Among 3 patients with LR 
in the navigated group, 2 had soft tissue involvement in the preoperative images. Nandra et al. 
recently reported that, among 23 patients with a primary pelvic or sacral tumour who underwent 
navigated resection, no bony recurrences were observed but 8 patients (35%) developed soft-tissue 
LR [29]. Owning to the limitation of the computer navigation for soft tissues, surgeons should be 
cautious in the management of soft tissue margins regardless of the use of the computer navigation.  
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 In this study, the difference in disease-specific survival between the groups did not reach 
statistical significance despite the introduction of c mputer navigation. Although some studies have 
suggested that wide resection margins are associated wi h a significant survival advantage [6], wide 
margins do not eliminate the possibility of metastatic disease and disease-specific death in patients 
with high-grade chondrosarcomas [7, 30, 31]. In this study, 24 of 26 patients (92%) with distant 
metastasis died of the disease. We realise that advncements in other treatment modalities, especially 
systemic treatment, for high-grade chondrosarcomas are crucial for improving disease-specific 
survival. Although literatures has shown the clinical benefit for the use of conventional 
chemotherapy [32-34] or targeted therapy [35], the efficacy has been limited to the dedifferentiated 
and mesehchymal subtypes or advanced/palliative settings. 
Recent studies have indicated that patient-specific instrumentation (PSI) can be used for 
bone resection with the same accuracy as computer navigation [36-38]. In addition, less resection 
time was required for PSI than for navigation in these reports [37, 38], although these investigations 
were cadaveric studies. At our institute, we do not use PSI for tumour resection. However, this new 
technology would not only improve accurate tumour resection but also reduce surgical time. 
 We acknowledge several limitations to this study. First, this study is a retrospective study 
conducted at a single referral centre without randomization. Although the study number is limited, no 
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significant differences were found in tumour- and trea ment-related variables between the navigated 
and non-navigated groups. The treatment strategy and surgical technique did not change throughout 
the study period except for the use of navigation. Second, the surgeon’s technical bias may have 
existed. All cases were performed by a single surgical team, consisting of the senior authors (LJ and 
RG), of which the navigated surgeries were carried out by the lead author (LJ) who received 
appropriate training on the navigation equipment before performing those resections. Third, a 
comparison of the navigated and non-navigated groups included a time effect based on the 
introduction of computer navigation in 2010. However, this bias would be minimal because no major 
difference was observed in the follow-up period between the navigated (mean, 65 months) and 
non-navigated groups (mean, 62 months). Finally, this study includes some bias based on technical 
factors and imaging studies, which improved over time. Improvements in surgical margins, in turn, 
might be achieved as a result of better imaging. Despit  these limitations, this is the first study, to the 
best of our knowledge, reporting the outcomes of navigated resection focussing on the periacetabular 
chondrosarcomas, providing the useful information to patients and treating surgeons. 
In conclusion, the navigation-assisted surgery for pelvic chondrosarcomas involving the 
acetabulum significantly decreased the intralesional margin rate and the risk of LR, and improved the 
progression-free survival with favourable functional outcome. We believe that these findings are 
 19
encouraging to orthopaedic oncologists for better management against chondrosarcomas whose 
outcome has been plateaued for more than 40 years. 
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Figure 1. (A) Preoperative planning. The tumour is highlighted in yellow. The resection line is 
marked in light blue. In this case, resection for anterior pelvis was planned at the symphysis pubis, in 
which the resection line was unnecessary. The custom-made implant is marked in green. (B) 
Postoperative radiograph. Custom-made implant was completely fitted to the osteotomy line. 
 
Figure 2. Competing analysis showing the cumulative incidence of local recurrence according to the 
surgical margin (A; p = 0.007; Gray’s test) and the use of navigation (B; p = 0.037; Gray’s test). 
 
Figure 3. Kaplan-Meier curve showing progression-free survival according to the use of navigation. 
p = 0.032; log-rank test. 
 
Figure 4. Kaplan-Meier curve showing disease-specific survival according to the use of navigation. 
p = 0.085; log-rank test. 
 
Table 1. Patient characteristics 
Variable 
Total Navigated Non-navigated 
p value 
Number Range, % Number Range, % Number Range, % 
No. of patients 50 – 13 – 37 – 
 
Age (mean, years) 53 20–77 55 20–77 53 31–75 0.750 
Gender       0.529 
  Male 36 72% 9 69% 27 73%  
  Female 14 28% 4 31% 10 27%  
Size (mean, cm) 10 5–20 10 5–20 10 5–20 0.752 
Grade 
      
0.463 
  Grade 1 7 14% 3 23% 4 11% 
 
  Grade 2 23 46% 7 54% 17 46% 
 
  Grade 3 12 24% 2 15% 9 24% 
 
  Dedifferentiated 8 16% 1 8% 7 19% 
 
Adjuvant therapy 
       
  Chemotherapy 3 6% 1 8% 2 5% 0.604 
  Radiotherapy 2 4% 1 8% 1 3% 0.456 
Type of surgery 
      
0.889 
  Custom-made EPR 23 46% 7 54% 16 43% 
 
  Ice-cream cone EPR 15 30% 3 23% 12 32% 
 
  Irradiated autograft 7 14% 2 15% 5 14% 
 
  Others (cemented THR, 
  hip transposition) 
5 10% 1 8% 4 11% 
 
Resected area 
      
0.374 
  PI uninvolved (PII, PII-III) 26 52% 5 46% 21 57% 
 
  PII 8 16% 2 15% 6 16%  
  PII–III 18 36% 3 23% 15 41%  
  PI involved (PI-II, PI-II-III) 24 48% 7 54% 16 43% 
 
  PI–II 16 32% 7 54% 9 25%  
  PI–II–III 8 16% 1 8% 7 19%  
Type of resection       0.301 
  Extra-articular 11 22% 4 31% 7 19%  
  Intra-articular 39 78% 9 69% 30 81%  
Surgical margin 
      
0.050 
  Wide 17 34% 8 61% 9  24% 
 
 Marginal 25 50% 4 31% 21 57%  
  Intralesional 8 16% 0: bone 1: soft tissue 8% 
6: bone 
1: soft tissue 19%  
Follow-up (mean, months) 63 5–154 65 15–107 62  5–154 0.837  
  





Gray's test Cox regression hazard model 




   




> 60 years 15 56% 
 




   




Female 14 43% 
 




   




> 8 cm 34 44% 
 




   




Grade 2 23 54% 
 
2.720 0.610–12.127 0.190 
Grade 3 12 42% 
 
2.347 0.453–12.166 0.310 
Dedifferentiated 8 50% 
 




   
Yes 3 67%  
1 Reference 
 
No 47 46%  




   




No 48 47% 
 




   




PI uninvolved (PII, PII-III) 26 33% 
 




   




Marginal 25 48% 
 
0.486 0.193–1.222 0.125 
Wide 17 24% 
 




   








Table 3. Postoperative complications 
 
Complication 
Total Navigated Non-navigated 
p value 
 Number % Number % Number % 
Mechanical complications 
       
 
Soft-tissue complication 
       
 
  Dislocation 16 32% 4 31% 12 32% 0.600 
 
Aseptic loosening 
       
 
  Early (≤2 years) 3 6% 0 0% 3 8% 0.396 
 
  Late (>2 years) 1 2% 1 8% 0 0% 0.260 
 
Structural complication 
       
 
  Implant 1 2% 1 8% 0 0% 0.260 
 
  Bone 3 6% 0 0% 3 8% 0.396 
Non-mechanical complications 
       
 
Infection 
       
 
  Deep 15 30% 4 31% 11 30% 0.602 
 
  Superficial 4 8% 0 0% 4 11% 0.287 
 Tumour progression        
   Local recurrence 24 48% 3 23% 21 57% 0.037 
   Distant metastasis 23 46% 4 31% 19 51% 0.170 
Other complications 
       
 
Deep-vein thrombosis 4 8% 1 8% 3 8% 0.725 
 
Nerve complication 4 8% 1 8% 3 8% 0.725 
 
Wound necrosis 2 4% 1 8% 1 3% 0.456 
 
Limb-length discrepancy 2 4% 1 8% 1 3% 0.456 
 
Pulmonary embolism 2 4% 1 8% 1 3% 0.456 
 
Lymphoedema 2 4% 0 0% 2 5% 0.544 
 
Visceral complication 2 4% 0 0% 2 5% 0.544 
 Heterotopic ossification 1 2% 1 8% 0 0% 0.260 
 
  
Table 4. Results of the Cox regression hazard model for PFS and DSS 
Variables N 
PFS DSS 
HR 95%CI p value HR 95%CI p value 
Age 
       




> 60 years 15 1.553 0.772–3.124 0.220 1.634 0.693–3.851 0.260 
Sex 
       




Female 14 0.946 0.408–2.191 0.900 1.383 0.564–3.393 0.480 
Size 
       




> 8 cm 34 1.223 0.589–2.536 0.590 4.148 1.280–13.440 0.018 
Histological grade 
       




Grade 2 23 2.851 0.645–12.602 0.167 26530 10100–6970 <0.001 
Grade 3 12 4.838 1.054–22.195 0.043 49210 17880–135400 <0.001 
Dedifferentiated 8 5.342 1.073–26.599 0.041 54960 14900–202800 <0.001 
Chemotherapy 
       




No 47 1.010 0.241–4.231 0.989 0.540 0.153–1.906 0.340 
Radiotherapy 
       




No 48 1.178 0.160–8.658 0.872 0.626 0.084–4.674 0.648 
Resected area 
       




PI uninvolved (PII, PII-III) 26 0.805 0.402–1.615 0.540 0.810 0.363–1.809 0.607 
Margin 
       




Marginal 25 0.704 0.293–1.692 0.433 0.683 0.262–1.783 0.436 
Wide 17 0.336 0.117–0.964 0.042 0.303 0.086–1.075 0.065 
Navigation 
       




Yes 13 0.387 0.154–0.973 0.044 0.444 0.133–1.481 0.190 
LR 
       
No 28 – – – 1 Reference 
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